A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation

Transplantation

Volumn 92, Issue 8, 2011, Pages 930-935

  Saitoh, Akihiko ^a   Sakamoto, Seisuke ^a   Fukuda, Akinari ^a   Shigeta, Takanobu ^a   Kakiuchi, Toshihiko ^a   Kamiyama, Shinya ^a   Katsuta, Tomohiro ^a   Shoji, Kensuke ^a   Ogimi, Chikara ^a   Kasahara, Mureo ^a  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Children; Cytomegalovirus; Ganciclovir; Liver transplantation; Preemptive therapy

Indexed keywords

FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; VALGANCICLOVIR;

ACUTE LIVER FAILURE; ARTICLE; BILE DUCT ATRESIA; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG USE; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; JAPAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVER TUMOR; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INFANT; LIVER TRANSPLANTATION; LIVING DONORS; MALE; PHOSPHOPROTEINS; VIRAL MATRIX PROTEINS;

EID: 80054742842     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822d873d     Document Type: Article

References (30)

1. Fridell JA, Jain A, Reyes J, et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. Transplantation 2002; 74: 1721.
2. Gupta P, Hart J, Cronin D, et al. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001; 72: 1098.
3. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106.
4. Kim JM, Lee SK, Kim SJ, et al. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia. Transplant Proc 2010; 42: 895.
5. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
6. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869.
7. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
8. Singh N, Wannstedt C, Keyes L, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85.
9. Singh N, Wannstedt C, Keyes L, et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 2008; 14: 240.
10. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in highrisk seropositive solid-organ transplant recipients. Transplantation 2006; 82: 30.
11. Madan RP, Campbell AL, Shust GF, et al. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation 2009; 87: 1318.
12. Gerna G, Lilleri D, Callegaro A, et al. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation 2008; 86: 163.
13. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
14. Martin JM, Danziger-Isakov LA. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation. Pediatr Transplant 2011;15:229-236.
15. Cytomegalovirus. Am J Transplant 2004; 4(suppl 10): 51.
16. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006; 71: 154.
17. Faqi AS, Klug A, Merker HJ, et al. Ganciclovir induces reproductive hazards in male rats after short-term exposure. Hum Exp Toxicol 1997; 16: 505.
18. Marshall BC, Koch WC. Antivirals for cytomegalovirus infection in neonates and infants: Focus on pharmacokinetics, formulations, dosing, and adverse events. Paediatr Drugs 2009; 11: 309.
19. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645.
20. Kusne S, Grossi P, Irish W, et al. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 1125.
21. Seehofer D, Meisel H, Rayes N, et al. Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation. Am J Transplant 2004; 4: 1331.
22. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811.
23. Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008; 197: 836.
24. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
25. Gerna G, Lilleri D, Zecca M, et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2005; 90: 526.
26. Gerna G, Sarasini A, Lilleri D, et al. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J Infect Dis 2003; 188: 1639.
27. Sano K, Tanaka K, Uemoto S, et al. Cytomegalovirus infection in living related liver transplantation: Rapid diagnosis by human monoclonal antibody staining of blood leucocytes. Transplant Sci 1994; 4: 105.
28. Shoji K, Ito N, Ito Y, et al. Is a 6-week course of ganciclovir therapy effective for chorioretinitis in infants with congenital cytomegalovirus infection? J Pediatr 2010; 157: 331.
29. Scott GM, Isaacs MA, Zeng F, et al. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol 2004; 74: 85.
30. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658.